Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2681-2690

  Weber, Axel ^a   Imisch, Patricia ^a   Bergmann, Eckhard ^a   Christiansen, Holger ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPLICON; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 2P; EXPRESSED SEQUENCE TAG; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE C MYB; ONCOGENE DDX1; ONCOGENE LPIN1; ONCOGENE NAG; ONCOGENE NSE1; ONCOGENE SDC1; ONCOGENE SMC6; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; TELOMERE; ADOLESCENT; CHILD; CHROMOSOME 2; FEMALE; GENETICS; INFANT; MALE; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL;

DDX1 PROTEIN, HUMAN; DEAD BOX PROTEIN; DNA; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RNA HELICASE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 2; DEAD-BOX RNA HELICASES; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA HELICASES; SURVIVAL ANALYSIS;

EID: 4344654349     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.192     Document Type: Article

References (49)

1. Schwab M, Alitalo K, Klempnauer KH, et al: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305:245-248, 1983
2. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
3. Brodeur GM, Maris JM, Yamashiro DJ, et al: Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93-101, 1997
4. Kawa K, Ohnuma N, Kaneko M, et al: Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 17:3216-3220, 1999
5. Brodeur GM, Seeger RC: Gene amplification in human neuroblastomas: Basic mechanisms and clinical implications. Cancer Genet Cytogenet 19:101-111, 1986
6. Squire JA, Thorner PS, Weitzman S, et al: Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 10:1417-1422, 1995
7. George RE, Kenyon RM, McGuckin AG, et al: Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group. Oncogene 12:1583-1587, 1996
8. George RE, Kenyon R, McGuckin AG, et al: Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 33:2037-2042, 1997
9. Manohar CF, Salwen HR, Brodeur GM, et al: Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. Genes Chromosomes Cancer 14:196-203, 1995
10. De Preter K, Speleman F, Combaret V, et al: Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 15:159-166, 2002
11. Scott DK, Board JR, Lu X, et al: The neuroblastoma amplified gene, NAG: Genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma. Gene 307:1-11, 2003
12. Reiter JL, Brodeur GM: High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics 32:97-103, 1996
13. Kent WJ: BLAT - The BLAST-like alignment tool. Genome Research 12:656-664, 2002
14. Tanner NK, Linder P: DExD/H box RNA helicases: From generic motors to specific dissociation functions. Mol Cell 8:251-262, 2001
15. Hashimoto K, Nakagawa Y, Morikawa H, et al: Co-overexpression of DEAD box protein rck/p54 and c-myc protein in human colorectal adenomas and the relevance of their expression in cultured cell lines. Carcinogenesis 22:1965-1970, 2001
16. Klappacher GW, Lunyak W, Sykes DB, et al: An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell 109:169-180, 2002
17. Godbout R, Squire J: Amplification of a DEAD box protein gene in retinoblastoma cell lines. Proc Natl Acad Sci U S A 90:7578-7582, 1993
18. Amler LC, Schurmann J, Schwab M: The DDX1 gene maps within 400 kbp 5′ to MYCN and is frequently coamplified in human neuroblastoma. Genes Chromosomes Cancer 15:134-137, 1996
19. Godbout R, Hale M, Bisgrove D: A human DEAD box protein with partial homology to heterogeneous nuclear ribonucleoprotein U. Gene 138:243-245, 1994
20. Pandita A, Godbout R, Zielenska M, et al: Relational mapping of MYCN and DDXI in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH. Genes Chromosomes Cancer 20:243-252, 1997
21. Wimmer K, Zhu XX, Lamb BJ, et al: Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. Oncogens 18:233-238, 1999
22. Fujioka Y, Kimata Y, Nomaguchi K, et al: Identification of a novel non-structural maintenance of chromosomes (SMC) component of the SMC5-SMC6 complex involved in DNA repair. J Biol Chem 277:21585-21591, 2002
23. Peterfy M, Phan J, Xu P, et al: Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 27:121-124, 2001
24. Taylor EM, Moghraby JS, Lees JH, et al: Characterization of a novel human SMC heterodimer homologous to the Schizosaccharomyces pombe Rad18/Spr18 complex. Mol Biol Cell 12:1583-1594, 2001
25. Ala-Kapee M, Nevanlinna H, Mali M, et al: Localization of gene for human syndecan, an integral membrane proteoglycan and a matrix receptor, to chromosome 2. Somat Cell Mol Genet 16:501-505, 1990
26. Alexander CM, Reichsman F, Hinkes MT, et al: Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25:329-332, 2000
27. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
28. Berthold F, Burdach S, Kremens B, et al: The role of chemotherapy in the treatment of children with neuroblastoma stage IV: The GPO (German Pediatric Oncology Society) experience. Klin Padiatr 202:262-269, 1990
29. Berthold F, Hero B: Neuroblastoma: Current drug recommendations as part of the total treatment approach. Drugs 59:1261-1277, 2000
30. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
31. Christiansen H, Sahin K, Berthold F, et al: Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 31A:541-544, 1995
32. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408, 2001
33. Beheshti B, Braude I, Marrano P, et al: Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia 5:53-62, 2003
34. Hirano T: The ABCs of SMC proteins: Two-armed ATPases for chromosome condensation, cohesion, and repair. Genes Dev 16:399-414, 2002
35. Chen B, Jhanwar SC, Ladanyi M: Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification. Diagn Mol Pathol 10:100-104, 2001
36. Schwab M, Ellison J, Busch M, et al: Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 81:4940-4944, 1984
37. Godbout R, Packer M, Bie W: Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem 273:21161-21168, 1998
38. Kiledjian M, Dreyfuss G: Primary structure and binding activity of the hnRNP U protein: Binding RNA through RGG box. EMBO J 11:2655-2664, 1992
39. Chen HC, Lin WC, Tsay YG, et al: An RNA helicase, DDX1, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K. J Biol Chem 277:40403-40409, 2002
40. Michael WM, Eder PS, Dreyfuss G: The K nuclear shuttling domain: A novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO J 16:3587-3598, 1997
41. Takimoto M, Tomonaga T, Matunis M, et al: Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J Biol Chem 268:18249-18258, 1993
42. Ostareck DH, Ostareck-Lederer A, Wilm M, et al: mRNA silencing in erythroid differentiation: HnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3′ end. Cell 89:597-606, 1997
43. Ostareck-Lederer A, Ostareck DH, Cans C, et al: C-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol 22:4535-4543, 2002
44. Borkhardt A, Cazzaniga G, Viehmann S, et al: Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 90:571-577, 1997
45. Busson-Le Coniat M, Nguyen Khac F, et al: Chromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia. Genes Chromosomes Cancer 32:244-249, 2001
46. Dal Cin P, Atkins L, Ford C, et al: Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer 30:407-409, 2001
47. Maloney K, McGavran L, Murphy J, et al: TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Leukemia 13:1708-1712, 1999
48. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al: TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 96:1094-1099, 2000
49. Krishna Narla R, Navara C, Sarquis M, et al: Chemosensitivity of TEL-AML1 fusion transcript positive acute lymphoblastic leukemia cells. Leuk Lymphoma 41:615-623, 2001